Novo Nordisk is launching its blockbuster weight loss drug Wegovy in China for a fraction of the US price, seeking to tap a vast market hit by rising obesity rates. A one-month supply of a starter dose of the Danish drugmaker’s appetite-blocking shot will cost 1,400 yuan ($193.45), Bloomberg reported, far lower than the $1,349 US list price. The drug’s arrival in China, where the number of obese people nearly tripled between 2004 and 2018, comes as the next generation of weight loss drugs promises to be even more effective than Wegovy. One new shot may solve the problem of patients regaining weight when they stop taking the drug, which “could usher in a whole new class of weight-loss treatments,” Bloomberg wrote. |